Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Pemetrexed (Alimta®): A new antifolate for non-small-cell lung cancer
David S. Ettinger
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Pemetrexed (Alimta®): A new antifolate for non-small-cell lung cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Pemetrexed
100%
Antifolate
100%
Alimta
100%
Response Rate
42%
Cisplatin
28%
Non-small Cell Lung Cancer Patients
28%
Chemotherapy
14%
Neutropenia
14%
Folate
14%
Median Survival
14%
Gemcitabine
14%
Nutritional Supplements
14%
Vitamin B12
14%
% Response
14%
Second-line Therapy
14%
Non-platinum
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Folic Acid Antagonist
100%
Pemetrexed
100%
Cisplatin
22%
Chemotherapy
11%
Folic Acid
11%
Gemcitabine
11%
Neutropenia
11%
Vitamin B12
11%
Nutrition Supplement
11%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Pemetrexed
100%
Antifolate
100%
Cisplatin
22%
Neutropenia
11%
Folic Acid
11%
Gemcitabine
11%
Nutrition Supplement
11%
Treatment of Non-Small Cell Lung Cancer
11%
Cyanocobalamin
11%